EAU 2013 - Programme Book - YouMed

Monday, 18 March - EAU Programme
Abstract Session
14.00 - 15.30 Renal tumours: Drug related basic research
Red Hall 2 - Level N1
Poster Session 80
Chairs: F. Birkhäuser, Berne (CH)
T. Klatte, Vienna (AT)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed
by 2 minutes for discussion.
975 Pre-clinical trial of a new dual mTOR inhibitor: INK128 for renal cell carcinoma
A. Ingels, A. Thong, M. Saar, M.P. Valta, R. Nolley, J. Santos, H. Zhao, D. Peehl (Stanford, United States of
America)
976 Panobinostat and bortezomib inhibit renal cancer growth in vitro and in vivo by inducing endoplasmic
reticulum stress and ubiquitinated protein accumulation synergistically
A. Sato, T. Asano, K. Ito, T. Asano (Tokorozawa, Japan)
977 Ritonavir, a potent inhibitor of CYP3A4, enhances the anticancer effects of panobinostat in renal cancer
cells in vitro and in vivo
A. Sato, T. Asano, K. Ito, T. Asano (Tokorozawa, Japan)
978 A novel therapeutic approach for renal cell cancer cells using orally available phenylpiperazine derivative
naftopidil
Y. Iwamoto, H. Kanda, M. Kato, T. Sasaki, K. Ishii, K. Arima, T. Shiraishi, Y. Sugimura (Tsu, Japan)
979 Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1
T. Kijima, F. Koga, Y. Fujii, S. Yoshida, M. Tatokoro, K. Kihara (Tokyo, Japan)
* 980 Optimization of Lutetium-177-G250 radioimmunotherapy in an intraperitoneal clear cell renal cell
carcinoma xenograft model
C.H.J. Muselaers, O.C. Boerman, D.L. Bos, W.J.G. Oyen, E. Oosterwijk, P.F.A. Mulders (Nijmegen, The
Netherlands)
981 Predictive value of angiogenic biomarkers in tuberous sclerosis complex (TSC) patients with renal
angiomyolipoma (AML)
K. Budde, J.C. Kingswood, T. Brechenmacher, K. Stein, D. Chen, J.J. Bissler (Berlin, Germany; Brighton,
United Kingdom; Rueil-Malmaison, France; East Hanover, New Jersey, Cincinnati, Ohio, United States of
America)
982 Sorafenib enhances the anti-tumor effect of anti-CTLA-4 antibody to kidney cancer
T. Motoshima, Y. Komohara, Y. Kawano, Y. Wada, M. Eto (Kumamoto, Japan)
983 Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation
of signal transduction pathways associated with tumor cell proliferation
H. Miyake, I. Sakai, M. Fujisawa (Kobe, Japan)
* 984 Potential predictive markers for a response to sunitinib and their association with survival of patients with
metastatic renal cell carcinoma
J. Dornbusch, M. Meinhardt, K. Erdmann, A. Zacharis, S. Zastrow, S. Füssel, M.P. Wirth (Dresden, Germany)
EAU Milan 2013
293
Monday